IL237424A0 - A two-layer tablet coating preparation containing atorvastatin, irvastatin, irvastatin and magnesium carbonate - Google Patents

A two-layer tablet coating preparation containing atorvastatin, irvastatin, irvastatin and magnesium carbonate

Info

Publication number
IL237424A0
IL237424A0 IL237424A IL23742415A IL237424A0 IL 237424 A0 IL237424 A0 IL 237424A0 IL 237424 A IL237424 A IL 237424A IL 23742415 A IL23742415 A IL 23742415A IL 237424 A0 IL237424 A0 IL 237424A0
Authority
IL
Israel
Prior art keywords
irbesartan
atorvastatin
magnesium carbonate
tablet formulation
composite tablet
Prior art date
Application number
IL237424A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50183917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL237424(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of IL237424A0 publication Critical patent/IL237424A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL237424A 2012-08-31 2015-02-25 A two-layer tablet coating preparation containing atorvastatin, irvastatin, irvastatin and magnesium carbonate IL237424A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120096477A KR20140028971A (ko) 2012-08-31 2012-08-31 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
PCT/KR2013/007838 WO2014035188A1 (en) 2012-08-31 2013-08-30 Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate

Publications (1)

Publication Number Publication Date
IL237424A0 true IL237424A0 (en) 2015-04-30

Family

ID=50183917

Family Applications (1)

Application Number Title Priority Date Filing Date
IL237424A IL237424A0 (en) 2012-08-31 2015-02-25 A two-layer tablet coating preparation containing atorvastatin, irvastatin, irvastatin and magnesium carbonate

Country Status (31)

Country Link
US (1) US20150209290A1 (enExample)
EP (1) EP2890368A4 (enExample)
JP (1) JP6363079B2 (enExample)
KR (1) KR20140028971A (enExample)
CN (1) CN104602677A (enExample)
AR (1) AR092386A1 (enExample)
AU (1) AU2013309686B2 (enExample)
BR (1) BR112015004471A8 (enExample)
CA (1) CA2882735A1 (enExample)
CL (1) CL2015000402A1 (enExample)
CR (1) CR20150115A (enExample)
DO (1) DOP2015000040A (enExample)
EA (1) EA030306B1 (enExample)
EC (1) ECSP15010600A (enExample)
GT (1) GT201500043A (enExample)
IL (1) IL237424A0 (enExample)
IN (1) IN2015DN01463A (enExample)
MA (1) MA37951B2 (enExample)
MX (1) MX354800B (enExample)
MY (1) MY175897A (enExample)
NI (1) NI201500027A (enExample)
NZ (1) NZ706472A (enExample)
PE (1) PE20150935A1 (enExample)
PH (1) PH12015500394A1 (enExample)
RU (1) RU2015111546A (enExample)
SG (1) SG11201500584YA (enExample)
TW (1) TWI651101B (enExample)
UA (1) UA115995C2 (enExample)
UY (1) UY35001A (enExample)
WO (1) WO2014035188A1 (enExample)
ZA (1) ZA201502156B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6981088B2 (ja) * 2017-01-27 2021-12-15 ニプロ株式会社 経口固形製剤
AU2018301924B2 (en) * 2017-07-17 2021-07-29 Eli Lilly And Company Pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
US20030114497A1 (en) 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
KR101230731B1 (ko) * 2008-04-29 2013-02-07 한올바이오파마주식회사 약제학적 제제
WO2011121824A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 口腔内崩壊錠
KR101248804B1 (ko) 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제

Also Published As

Publication number Publication date
GT201500043A (es) 2017-08-24
US20150209290A1 (en) 2015-07-30
JP2015530384A (ja) 2015-10-15
MX2015002526A (es) 2015-06-23
ECSP15010600A (es) 2015-12-31
EP2890368A4 (en) 2016-03-02
KR20140028971A (ko) 2014-03-10
CL2015000402A1 (es) 2015-06-05
PE20150935A1 (es) 2015-06-20
NZ706472A (en) 2018-02-23
TW201414507A (zh) 2014-04-16
UA115995C2 (uk) 2018-01-25
BR112015004471A8 (pt) 2019-08-27
BR112015004471A2 (pt) 2017-07-04
AU2013309686A1 (en) 2015-02-26
IN2015DN01463A (enExample) 2015-07-03
UY35001A (es) 2014-03-31
MA37951B2 (fr) 2019-12-31
CA2882735A1 (en) 2014-03-06
EP2890368A1 (en) 2015-07-08
DOP2015000040A (es) 2015-04-15
ZA201502156B (en) 2016-07-27
AU2013309686B2 (en) 2017-09-07
JP6363079B2 (ja) 2018-07-25
RU2015111546A (ru) 2016-10-20
WO2014035188A1 (en) 2014-03-06
CN104602677A (zh) 2015-05-06
SG11201500584YA (en) 2015-02-27
AR092386A1 (es) 2015-04-22
NI201500027A (es) 2017-01-04
MY175897A (en) 2020-07-14
CR20150115A (es) 2015-04-16
MA37951A1 (fr) 2018-06-29
PH12015500394A1 (en) 2015-04-27
EA030306B1 (ru) 2018-07-31
EA201590469A1 (ru) 2015-06-30
MX354800B (es) 2018-03-22
TWI651101B (zh) 2019-02-21

Similar Documents

Publication Publication Date Title
EP2875959A4 (en) PRINTING MACHINE AND TABLET ASSOCIATED
PH12013500299A1 (en) Pyrrolopyrimidine compounds and uses thereof
EP2599471A4 (en) Tablet splitting device
PL2469142T3 (pl) Złączka zaciskowa i jej zastosowanie
EP2877287A4 (en) PILL CRUSHING SYSTEM
GB2489658B (en) Tablet press
PT2864113T (pt) Prensa de comprimido
EP2822931A4 (en) TRIAZOLONE COMPOUNDS AND USES THEREOF
EP2917393A4 (en) NONWOVEN AND EXPANDABLE LAMINATE
IL223012B (en) Pharmacy preparations in the form of tablets with two layers containing atorvastatin and irbesartan
PL2488043T5 (pl) Udoskonalona tabletka odżywcza
ZA201405581B (en) Gastroretentive tablets
ZA201409508B (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
IL239372B (en) Triazolone compounds and their uses
ZA201502157B (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
GB2483309B (en) Tablet Case with rottable handle
GB201020399D0 (en) Safety unit
GB201007202D0 (en) Product and uses
EP2687083A3 (de) Ballenpresse
IL229206A0 (en) Preparation and tablet containing raltagravir
ZA201502156B (en) Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate
PT2593081E (pt) Composição de comprimido à base de ferrimanitol ovalbumina
PL2651390T3 (pl) Orodyspersyjna tabletka farmaceutyczna na bazie zolpidemu
ZA201405354B (en) Antacid tablet
GB201214923D0 (en) Baling presses